Pharmaceutical compositions containing a combination of rhizoma coptidis and a herbal composition comprises at least one herb selected from the group consisting of Radix Ginseng, Poria, Rhizoma Atractylodis macrocephalae, Semen Lablab album, Rhizoma Dioscoreae, Embryo Nelumbinis, Radix Platycodonis, Semen Coicis, Fructus Amomi, Fructus Jujubae and Radix Glycyrrhizae are disclosed. Methods of treating diseases by administering an effective amount of the pharmaceutical composition are also provided.

The present invention provides a pharmaceutical composition for preventing or treating cancer, a food composition for enhancing immune functions, and a pharmaceutical composition for preventing or treating cachexia. The composition of the present invention provides effects of further inhibiting the growth of tumors, increasing immunological activity, and suppressing cachexia caused by tumors. In addition, the composition of the present invention can obtain a synergistic effect when co-administered with an existing anticancer drug.

The present invention provides a pharmaceutical composition for preventing or treating cancer, a food composition for enhancing immune functions, and a pharmaceutical composition for preventing or treating cachexia. The composition of the present invention provides effects of further inhibiting the growth of tumors, increasing immunological activity, and suppressing cachexia caused by tumors. In addition, the composition of the present invention can obtain a synergistic effect when co-administered with an existing anticancer drug.

The present invention provides a pharmaceutical composition for preventing or treating cancer, a food composition for enhancing immune functions, and a pharmaceutical composition for preventing or treating cachexia. The composition of the present invention provides effects of further inhibiting the growth of tumors, increasing immunological activity, and suppressing cachexia caused by tumors. In addition, the composition of the present invention can obtain a synergistic effect when co-administered with an existing anticancer drug.

A method for regulating blood glucose level is provided. The method comprises administering to a subject in need an effective amount of at least one of poricoic acid A and poricoic acid B, wherein at least one of poricoic acid A and poricoic acid B can be used in the form of a plant extract, and wherein in the plant extract, poricoic acid A and poricoic acid B are present in a total amount of at least 30 wt %, based on the total weight of the plant extract.

A method for regulating blood glucose level is provided. The method comprises administering to a subject in need an effective amount of at least one of poricoic acid A and poricoic acid B, wherein at least one of poricoic acid A and poricoic acid B can be used in the form of a plant extract, and wherein in the plant extract, poricoic acid A and poricoic acid B are present in a total amount of at least 30 wt %, based on the total weight of the plant extract.

The present invention discloses a novel use of a lanostane having the following formula (I) in enhancing uptake of nutrients: ##STR00001##
wherein R.sub.1 is either H or CH.sub.3; R.sub.2 is OCOCH.sub.3, ═O or OH; R.sub.3 is H or OH; R.sub.4 is —C(═CH.sub.2)—C(CH.sub.3).sub.2R.sub.a, in which R.sub.a is H or OH, or —CH═C(CH.sub.3)—R.sub.b, in which R.sub.b is CH.sub.3 or CH.sub.2OH; R.sub.5 is H or OH; and R.sub.6 is CH.sub.3 or CH.sub.2OH.

The present invention discloses a novel use of a lanostane having the following formula (I) in enhancing uptake of nutrients: ##STR00001##
wherein R.sub.1 is either H or CH.sub.3; R.sub.2 is OCOCH.sub.3, ═O or OH; R.sub.3 is H or OH; R.sub.4 is —C(═CH.sub.2)—C(CH.sub.3).sub.2R.sub.a, in which R.sub.a is H or OH, or —CH═C(CH.sub.3)—R.sub.b, in which R.sub.b is CH.sub.3 or CH.sub.2OH; R.sub.5 is H or OH; and R.sub.6 is CH.sub.3 or CH.sub.2OH.

The present invention discloses a novel use of a lanostane having the following formula (I) in enhancing uptake of nutrients: ##STR00001##
wherein R.sub.1 is either H or CH.sub.3; R.sub.2 is OCOCH.sub.3, ═O or OH; R.sub.3 is H or OH; R.sub.4 is —C(═CH.sub.2)—C(CH.sub.3).sub.2R.sub.a, in which R.sub.a is H or OH, or —CH═C(CH.sub.3)—R.sub.b, in which R.sub.b is CH.sub.3 or CH.sub.2OH; R.sub.5 is H or OH; and R.sub.6 is CH.sub.3 or CH.sub.2OH.

An embodiment of the present invention provides an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine, including: an ephedra powder agent of which ephedrine content is concentrated to be 3.0 to 4.0%, which is greater than 0.5 to 2.5% when it is in a natural state, and of which the ephedrine content is maintained constant at 3.0 to 4.0%; and a side-effect-preventing powder agent for each constitution prescribed based on Sasang constitutional medicine in order to prevent a side effect of the ephedra powder agent, wherein a weight ratio of the ephedra powder agent and the side-effect-preventing powder agent is 8-10:1 to 9-11:1.